Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

@article{Choopanya2013AntiretroviralPF,
  title={Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial},
  author={Kachit Choopanya and Michael Martin and Pravan Suntharasamai and Udomsak Sangkum and Philip A Mock and Manoj Leethochawalit and Sithisat Chiamwongpaet and Praphan Kitisin and Pitinan Natrujirote and Somyot Kittimunkong and Rutt Chuachoowong and Roman J. Gvetadze and Janet M Mcnicholl and Lynn A. Paxton and Marcel E. Curlin and Craig W. Hendrix and Suphak Vanichseni},
  journal={The Lancet},
  year={2013},
  volume={381},
  pages={2083-2090}
}

Figures and Tables from this paper

Risk Behaviors and Risk Factors for HIV Infection among Participants in the Bangkok Tenofovir Study, an HIV Pre-Exposure Prophylaxis Trial among People Who Inject Drugs
TLDR
Young age, needle sharing, and incarceration were independently associated with HIV infection, suggesting that the reduction in HIV incidence among participants taking daily oral tenofovir compared to those taking placebo was due to a decrease in parenteral HIV transmission.
Assessment of Oral Fluid HIV Test Performance in an HIV Pre-Exposure Prophylaxis Trial in Bangkok, Thailand
TLDR
The oral fluid HIV test performed well at screening, suggesting it can be used when rapid results and non-invasive tools are preferred, and among people using pre-exposure prophylaxis, a blood-based HIV test may be an appropriate choice.
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
TLDR
The use of TDF-FTC before and after sexual activity provided protection against HIV-1 infection in men who have sex with men, and the treatment was associated with increased rates of gastrointestinal and renal adverse events.
Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?
TLDR
A well-considered modeling exercise of the type the authors have come to expect from the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) group is presented, demonstrating potential advantages and costs, as well as cost-effectiveness thresholds for the use of long-acting injectable PrEP for young South African women.
Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States
TLDR
An empirically calibrated dynamic compartmental model of the U.S. HIV epidemic was developed and new clinical trial results with epidemiologic and economic data were incorporated to determine the optimal conditions under which PrEP can be delivered to this high-risk population.
HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial
TLDR
No clinically significant differences in HIV seroconversion outcomes were observed among women randomized to tenofovir-containing oral or vaginal PrEP regimens, however low overall adherence limits the generalizability of these findings.
...
...

References

SHOWING 1-10 OF 42 REFERENCES
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
TLDR
Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual men and women, and both study medications significantly reduced the HIV- 1 incidence among both men andWomen.
Enrollment Characteristics and Risk Behaviors of Injection Drug Users Participating in the Bangkok Tenofovir Study, Thailand
TLDR
Tenofovir Study participants are significantly less likely to report injecting drugs and sharing needles than participants in the 1999–2003 AIDSVAX B/E Vaccine Trial suggesting HIV incidence will be lower than expected.
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
TLDR
Despite the successful completion of this efficacy trial of AIDSVAX B/E (VaxGen), the vaccine did not prevent HIV-1 infection or delay HIV- 1 disease progression.
Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand
TLDR
HIV-1 transmission risk remains high among Bangkok IDUs despite methadone treatment and other current prevention strategies, and this study led to the initiation in 1999 of a phase III HIV-1 vaccine efficacy trial in this population.
Preexposure prophylaxis for HIV infection among African women.
TLDR
Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo, and drug adherence appeared to be low.
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
TLDR
Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults and had a significant decline in bone mineral density, which remains unknown.
O11.1 Herpes Simplex Virus (HSV) Infection in the VOICE (MTN 003) Study: Pre-Exposure Prophylaxis (PrEP) For HIV with Daily Use of Oral Tenofovir, Oral Tenofovir-Emtricitabine, or Vaginal Tenofovir Gel
TLDR
In this population of women at risk for HIV-1, seroprevalence of HSV-2 was high, with potentially important differences by age and site of enrollment.
Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
TLDR
Interim guidance to health-care providers is provided based on the reported results of the iPrEX trial, which indicated that TDF plus FTC taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling.
Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010
TLDR
The major changes from the Thai 2008 guidelines include commencing ART earlier and efavirenz is now considered a preferred NNRTI, along with nevirapine.
...
...